| Submission | Jan. 29, 2025 |
| Submission [Line Items] | |
| Central Index Key | 0001744659 |
| Registrant Name | Akero Therapeutics, Inc. |
| Registration File Number | 333-279338 |
| Form Type | S-3 |
| Submission Type | 424B5 |
| Fee Exhibit Type | EX-FILING FEES |
| Offerings | Jan. 29, 2025 USD ($) shares |
| Offering: 1 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Common Stock, $0.0001 par value per share |
| Amount Registered | shares | 8,385,417 |
| Proposed Maximum Offering Price per Unit | 48 |
| Maximum Aggregate Offering Price | $ 402,500,016 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 61,622.76 |
| Offering Note | (1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended. Represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on Form S-3ASR (Registration No. 333-279338) being paid herewith. (2) Includes 1,093,750 shares of common stock that the underwriters have an option to purchase and 1,958,247 shares of common stock that are issuable upon the exercise of the pre-funded warrants referenced below. |
| Offering: 2 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Pre-funded warrants to purchase Common Stock |
| Amount Registered | shares | 1,958,247 |
| Proposed Maximum Offering Price per Unit | 48 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 0 |
| Offering Note | (1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended. Represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on Form S-3ASR (Registration No. 333-279338) being paid herewith. (3) Represents the sum of the offering price of $47.9999 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants. |
| Fees Summary | Jan. 29, 2025 USD ($) |
| Fees Summary [Line Items] | |
| Total Offering | $ 402,500,016 |
| Previously Paid Amount | 0 |
| Total Fee Amount | 61,622.76 |
| Total Offset Amount | 0 |
| Net Fee | $ 61,622.76 |
